



Atty. Dkt. No. 029099-0106

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

U.S. Patent No. 5,888,510

Issued: March 30, 1999

Inventors: Tadamitsu KISHIMOTO et al.

Applicants: Chugai Seiyaku Kabushiki Kaisha  
Tadamitsu Kishimoto

Product: Actemra® (tocilizumab), humanized  
anti-human IL-6R monoclonal antibody

**TRANSMITTAL**

Mail Stop Hatch Waxman PTE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Please find enclosed the following documents filed in connection with the above referenced patent:

1. Hoffman-La Roche regulatory activity authorization letter in support of Application for Extension of Patent Term Under 35 USC §156.
2. Submission under 37 CFR §1.765 to support previously filed Application for Extension of Patent Term Under 35 USC § 156.

Respectfully submitted,

Date March 8, 2010

By 

FOLEY & LARDNER LLP  
Foley & Lardner LLP  
3000 K Street, N.W.  
Washington, D.C. 20007-5143  
Tel: 202-672-5300  
Facsimile: 202-672-5399

Stephen B. Maebius  
Attorney for Applicant  
Registration No. 35,264

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


U.S. Patent No. 5,888,510

Issued: March 30, 1999

Inventors: Tadamitsu KISHIMOTO et al.

Applicants: Chugai Seiyaku Kabushiki Kaisha  
Tadamitsu Kishimoto

Product: Actemra® (tocilizumab), humanized anti-human IL-6R monoclonal antibody



**SUBMISSION UNDER 37 CFR § 1.765 TO SUPPORT**  
**PREVIOUSLY FILED APPLICATION FOR PATENT TERM EXTENSION**  
**UNDER 35 U.S.C. §156**

Mail Stop: Hatch Waxman PTE  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir or Madam:

Applicant hereby advises the U.S. Patent and Trademark Office that applications for extension of the term of U.S. Patent Nos. 5,795,965 and 5,670,373 have been filed which are also based on the regulatory approval of a Biologics License Application (BLA # 125276/0) on January 8, 2010, for Actemra® (tocilizumab)

Respectfully submitted,

Date March 8, 2010

By \_\_\_\_\_

Stephen B. Maebius  
 Attorney for Applicant  
 Registration No. 35,264

FOLEY & LARDNER LLP  
 Foley & Lardner LLP  
 3000 K Street, N.W.  
 Washington, D.C. 20007-5143  
 Tel: 202-672-5300  
 Facsimile: 202-672-5399

**George W. Johnston**  
Vice President and Chief Patent Counsel  
Patent Law



March 8, 2010


Mr. Manabu Takahama  
Chugai Pharmaceutical Co., Ltd.  
Intellectual Property Department  
200 Kajiwara, Kamakura  
Kanagawa, 247-8530 JAPAN

Re: Actemra® Infusion Approval - USA

Dear Mr. Takahama,

By this letter, Hoffmann-La Roche Inc. ("Roche"), the holder of the BLA for Actemra®, confirms its prior and continuing authorization for Chugai Pharmaceutical Co., Ltd. ("Chugai") to rely upon Roche's regulatory activities with respect to Actemra® before the United States Food and Drug Administration ("FDA") as a basis for the recently filed applications to extend the terms of US Patent Nos. 5,795,965; 5,670,373; and 5,888,510. Roche's BLA 125276/0 was submitted on November 19, 2007 and references IND No. 11972 filed on October 5, 2004. As you know, the FDA approved Actemra® for marketing by Roche in the USA on January 8, 2010.

Please feel free to submit this correspondence to the United States Patent and Trademark Office as a confirmation of our authorization to Chugai.

Very truly yours,  
  
George W. Johnston